Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting

Journal of Clinical Investigation

Volumn 115, Issue 2, 2005, Pages 451-458

  Song, Yao Hua ^a   Li, Yangxin ^a   Du, Jie ^b   Mitch, William E ^b   Rosenthal, Nadia ^c   Delafontaine, Patrick ^a,d  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANGIOTENSIN; CASPASE 3; MESSENGER RNA; PROTEIN KINASE B; PROTEIN P70; RENIN; SOMATOMEDIN C; TARGET OF RAPAMYCIN KINASE; UBIQUITIN PROTEIN LIGASE; AKT1 PROTEIN, RAT; ANGIOTENSIN II; FBXO32 PROTEIN, MOUSE; FBXO32 PROTEIN, RAT; MAMMALIAN TARGET OF RAPAMYCIN; MUSCLE PROTEIN; ONCOPROTEIN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; RNF28 PROTEIN, RAT; S6 KINASE; TRIM63 PROTEIN, HUMAN; TRIM63 PROTEIN, MOUSE; VASOCONSTRICTOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CACHEXIA; CATABOLISM; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DOWN REGULATION; MOUSE; MUSCLE ATROPHY; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE; WASTING SYNDROME;

ANGIOTENSIN II; ANIMALS; CACHEXIA; HEART FAILURE, CONGESTIVE; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, TRANSGENIC; MUSCLE PROTEINS; MUSCLE, SKELETAL; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES; VASOCONSTRICTOR AGENTS; WASTING SYNDROME;

EID: 14844336534     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI22324     Document Type: Article

References (60)

1. Levenson, J.W., Skerrett, P.J., and Gaziano, J.M. 2002. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev. Cardiol. 5:188-199.
2. Kuroda, T., and Shida, H. 1983. Angiotensin II-induced myocardial damage with a special reference to low cardiac output syndrome. Jpn. Heart J. 24:235-243.
3. Anker, S.D., et al. 1997. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 349:1050-1053.
4. Anker, S.D., and Rauchhaus, M. 1999. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Curr. Opin. Cardiol. 14:211-216.
5. Brink, M., Wellen, J., and Delafontaine, P. 1996. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 97:2509-2516.
6. Sandri, M., et al. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117:399-412.
7. Lecker, S.H., et al. 2004. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18:39-51.
8. Vescovo, G., et al. 2000. Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart. 84:431-437.
9. Agusti, A.G., et al. 2002. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166:485-489.
10. Du, J., et al. 2004. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J. Clin. Invest. 113:115-123. doi: 10.1172/JCI200418330.
11. Bark, T.H., McNurlan, M.A., Lang, C.H., and Garlick, P.J. 1998. Increased protein synthesis after acute IGF-I or insulin infusion is localized to muscle in mice. Am. J. Physiol. 275:E118-E123.
12. Barton, E.R., Morris, L., Musaro, A., Rosenthal, N., and Sweeney, H.L. 2002. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 157:137-148.
13. Bodine, S.C., et al. 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294:1704-1708.
14. Goll, D.E., Thompson, V.F., Li, H., Wei, W., and Cong, J. 2003. The calpain system. Physiol. Rev. 83:731-801.
15. Tidball, J.G., and Spencer, M.J. 2002. Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J. Physiol. 545:819-828.
16. Neumar, R.W., Xu, Y.A., Gada, H., Guttmann, R.P., and Siman, R. 2003. Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J. Biol. Chem. 278:14162-14167.
17. Suhara, T., Kim, H.S., Kirshenbaum, L.A., and Walsh, K. 2002. Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol. Cell. Biol. 22:680-691.
18. Folli, F., Kahn, C.R., Hansen, H., Bouchie, J.L., and Feener, E.P. 1997. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J. Clin. Invest. 100:2158-2169.
19. Velloso, L.A., et al. 1996. Cross-talk between the insulin and angiotensin signaling systems. Proc. Natl. Acad. Sci. U. S. A. 93:12490-12495.
20. Motley, E.D., et al. 2003. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. Hypertension. 41:775-780.
21. Tseng, Y.H., Ueki, K., Kriauciunas, K.M., and Kahn, C.R. 2002. Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin. J. Biol. Chem. 277:31601-31611.
22. Chandrashekhar, Y., Sen, S., Anway, R., Shuros, A., and Anand, I. 2004. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J. Am. Coll. Cardiol. 43:295-301.
23. Grady, E.F., Sechi, L.A., Griffin, C.A., Schambelan, M., and Kalinyak, J.E. 1991. Expression of AT2 receptors in the developing rat fetus. J. Clin. Invest. 88:921-933.
24. Tsutsumi, K., Stromberg, C., Viswanathan, M., and Saavedra, J.M. 1991. Angiotensin-II receptor subtypes in fetal tissue of the rat: autoradiography, guanine nucleotide sensitivity, and association with phosphoinositide hydrolysis. Endocrinology. 129:1075-1082.
25. Brink, M., et al. 2001. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology. 142:1489-1496.
26. Auclair, D., Garrel, D.R., Chaouki Zerouala, A., and Ferland, L.H. 1997. Activation of the ubiquitin pathway in rat skeletal muscle by catabolic doses of glucocorticoids. Am. J. Physiol. 272:C1007-C1016.
27. Gayan-Ramirez, G., Vanderhoydonc, F., Verhoeven, G., and Decramer, M. 1999. Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am. J. Respir. Crit. Care Med. 159:283-289.
28. May, R.C., Kelly, R.A., and Mitch, W.E. 1986. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J. Clin. Invest. 77:614-621.
29. Mitch, W.E., et al. 1999. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am. J. Physiol. 276:C1132-C1138.
30. Price, S.R., England, B.K., Bailey, J.L., Van Vreede, K., and Mitch, W.E. 1994. Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. Am. J. Physiol. 267:C955-C960.
31. Youssef, J.A., and Badr, M.Z. 2003. Hepatocarcinogenic potential of the glucocorticoid antagonist RU486 in B6C3F1 mice: effect on apoptosis, expression of oncogenes and the tumor suppressor gene p53. Mol. Cancer. 2:3.
32. Musaro, A., et al. 2001. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 27:195-200.
33. Datta, S.R., et al. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
34. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. 1997. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 278:687-689.
35. Sjogren, K., et al. 1999. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. U. S. A. 96:7088-7092.
36. Yakar, S., et al. 1999. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 96:7324-7329.
37. Wing, S.S., and Goldberg, A.L. 1993. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am. J. Physiol. 264:E668-E676.
38. May, R.C., Bailey, J.L., Mitch, W.E., Masud, T., and England, B.K. 1996. Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. Kidney Int. 49:679-683.
39. Musaro, A., and Rosenthal, N. 1999. Maturation of the myogenic program is induced by postmitotic expression of insulin-like growth factor I. Mol. Cell. Biol. 19:3115-3124.
40. Fryburg, D.A., Jahn, L.A., Hill, S.A., Oliveras, D.M., and Barrett, E.J. 1995. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J. Clin. Invest. 96:1722-1729.
41. DeVol, D.L., Rotwein, P., Sadow, J.L., Novakofski, J., and Bechtel, P.J. 1990. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am. J. Physiol. 259:E89-E95.
42. Rommel, C., et al. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/ Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3:1009-1013.
43. Glass, D.J. 2003. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat. Cell Biol. 5:87-90.
44. Duncan, A.M., Burrell, L.M., Kladis, A., and Campbell, D.J. 1997. Angiotensin and bradykinin peptides in rats with myocardial infarction. J. Card. Fail. 3:41-52.
45. Nave, B.T., Ouwens, M., Withers, D.J., Alessi, D.R., and Shepherd, P.R. 1999. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344:427-431.
46. Beugnet, A., Tee, A.R., Taylor, P.M., and Proud, C.G. 2003. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem. J. 372:555-566.
47. Liu, Z., Jahn, L.A., Wei, L., Long, W., and Barrett, E.J. 2002. Amino acids stimulate translation initiation and protein synthesis through an Akt-independent pathway in human skeletal muscle. J. Clin. Endocrinol. Metab. 87:5553-5558.
48. Vescovo, G., et al. 2002. L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am. J. Physiol., Cell Physiol. 283:C802-C810.
49. Adams, V., et al. 1999. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. 33:959-965.
50. Hambrecht, R., et al. 2002. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J. Am. Coll. Cardiol. 39:1175-1181.
51. Anker, S.D., et al. 1997. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol. 30:997-1001.
52. Pedersen, E.B., et al. 1986. Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure. Eur. J. Clin. Invest. 16:56-60.
53. Staroukine, M., Devriendt, J., Decoodt, P., and Verniory, A. 1984. Relationships between plasma epinephrine, norepinephrine, dopamine and angiotensin II concentrations, renin activity, hemodynamic state and prognosis in acute heart failure. Acta Cardiol. 39:131 -138.
54. Ladner, K.J., Caligiuri, M.A., and Guttridge, D.C. 2003. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J. Biol. Chem. 278:2294-2303.
55. Reid, M.B., Lannergren, J., and Westerblad, H. 2002. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am. J. Respir. Crit. Care Med. 166:479-484.
56. Anker, S.D., et al. 1999. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur. Heart J. 20:683-693.
57. Anker, S.D., et al. 1997. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 96:526-534.
58. Kasahara, Y., et al. 2000. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. 106:1311-1319.
59. Davani, S., et al. 2003. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation. 108(Suppl 1):II253-II258.
60. Bundgaard, H., and Kjeldsen, K. 2002. Potassium depletion increases potassium clearance capacity in skeletal muscles in vivo during acute repletion. Am. J. Physiol., Cell Physiol. 283:C1163-C1170.